Literature DB >> 10972657

Estimating prevalence in single-gene kidney diseases progressing to renal failure.

M Levy1, J Feingold.   

Abstract

Incidence and prevalence, the measures of "frequency, " are often confused. While in a nonhereditary situation, the useful parameter is the incidence rate, evaluating the impact of an etiologic factor, it is prevalence that is considered useful in a hereditary disease. Prevalence may concern either the whole population or a fraction of this population, that is, males or females or individuals at a given age, for example, at birth. Pathologic phenotype and morbid genotype prevalences have to be clearly differentiated. In this article, we review the epidemiologic surveys allowing an estimation of the distribution of major single-gene kidney diseases progressing to renal failure in different populations. In order to compare their results, the geographic/ethnic composition of the population, the determination of its size, the choice and mode of calculation of the epidemiologic measure, the definition of the disease and modes of diagnosis, the inclusion of cases, the sources of ascertainment and the possible causes of underascertainment, and the period of time during which events were counted should be analyzed accurately. Although their impact in terms of morbidity, hospitalizations, mortality, and cost to society is high, this review shows that information on the prevalence of single-gene kidney diseases is far from complete. To date, the data essentially apply to large populations of European origin. A part of the variation among prevalence data may be due to methodological differences. Not representative are the small populations in which some rare diseases, especially recessive, are found with a high prevalence.

Entities:  

Mesh:

Year:  2000        PMID: 10972657     DOI: 10.1046/j.1523-1755.2000.00250.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  62 in total

1.  Cardiac abnormalities in primary hyperoxaluria.

Authors:  Farouk Mookadam; Travis Smith; Panupong Jiamsripong; Sherif E Moustafa; Carla G Monico; John C Lieske; Dawn S Milliner
Journal:  Circ J       Date:  2010-09-29       Impact factor: 2.993

2.  Nine novel COL4A3 and COL4A4 mutations and polymorphisms identified in inherited membrane diseases.

Authors:  Kesha Rana; Stephen Tonna; Yan Yan Wang; Lydia Sin; Tina Lin; Elizabeth Shaw; Ishanee Mookerjee; Judy Savige
Journal:  Pediatr Nephrol       Date:  2007-01-10       Impact factor: 3.714

3.  The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial.

Authors:  Satoru Muto; Haruna Kawano; Eiji Higashihara; Ichiei Narita; Yoshifumi Ubara; Takayuki Matsuzaki; John Ouyang; Vicente E Torres; Shigeo Horie
Journal:  Clin Exp Nephrol       Date:  2015-02-07       Impact factor: 2.801

Review 4.  Living donor kidney transplantation in patients with hereditary nephropathies.

Authors:  Patrick Niaudet
Journal:  Nat Rev Nephrol       Date:  2010-09-28       Impact factor: 28.314

5.  Improving mutation screening in familial hematuric nephropathies through next generation sequencing.

Authors:  Vincent Morinière; Karin Dahan; Pascale Hilbert; Marieline Lison; Said Lebbah; Alexandra Topa; Christine Bole-Feysot; Solenn Pruvost; Patrick Nitschke; Emmanuelle Plaisier; Bertrand Knebelmann; Marie-Alice Macher; Laure-Hélène Noel; Marie-Claire Gubler; Corinne Antignac; Laurence Heidet
Journal:  J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 10.121

6.  Patient-iPSC-Derived Kidney Organoids Show Functional Validation of a Ciliopathic Renal Phenotype and Reveal Underlying Pathogenetic Mechanisms.

Authors:  Thomas A Forbes; Sara E Howden; Kynan Lawlor; Belinda Phipson; Jovana Maksimovic; Lorna Hale; Sean Wilson; Catherine Quinlan; Gladys Ho; Katherine Holman; Bruce Bennetts; Joanna Crawford; Peter Trnka; Alicia Oshlack; Chirag Patel; Andrew Mallett; Cas Simons; Melissa H Little
Journal:  Am J Hum Genet       Date:  2018-04-26       Impact factor: 11.025

7.  Alport syndrome: a rare cause of uraemia.

Authors:  Soumik Ghosh; Manavdeep Singh; Ratnakar Sahoo; Sachin Rao
Journal:  BMJ Case Rep       Date:  2014-02-13

8.  Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease.

Authors:  Kevin F Erickson; Glenn M Chertow; Jeremy D Goldhaber-Fiebert
Journal:  Ann Intern Med       Date:  2013-09-17       Impact factor: 25.391

9.  Polycystic kidney disease and chronic renal failure in tuberous sclerosis.

Authors:  Mona Dhakal; O P Dhakal; Dhurba Bhandari
Journal:  BMJ Case Rep       Date:  2013-10-02

10.  Alport retinopathy results from "severe" COL4A5 mutations and predicts early renal failure.

Authors:  Rachel Tan; Deb Colville; Yan Yan Wang; Lin Rigby; Judy Savige
Journal:  Clin J Am Soc Nephrol       Date:  2009-12-03       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.